Arijit Chakravarty
Many a drug discovery program meets its end in the mouse room. Others make it out of preclinical pharmacology mortally wounded, the seeds of ultimate failure embedded in the choices that were made at this stage of development.
Read More →
Arijit Chakravarty
In the biotech/pharma industry, drug development projects hold the power to make or break companies and careers. It’s hard enough as it is to get a molecule to the finish line, but a tight market for funding can make that so much more difficult!
Read More →
Arijit Chakravarty
We’ve all heard the numbers - ten years, a billion dollars, and a 90% failure rate. Why is it so slow, expensive, and risky to take a drug candidate through the approval process?
Read More →
Arijit Chakravarty
A drug discovery program at its inception can feel like such a gamble. The biology is often still being understood, and it’s often unclear whether the chemistry will cooperate.
Read More →